Biomedical Data Science
2025, VOL. 5, NO. 1, 129-134
DOI: 10.47297/wspbdsWSP2752-630529.20250501

The Role of Ras Gene in Cancer and Progress in Antibody Research

Guoliang Ma

Puyang Medical College, Puyang, Henan, 457000, China

ABSTRACT
This review seeks to elucidate the significant function of the Ras gene in the pathogenesis of cancer as well as the latest advancements in antibody research aimed at targeting Ras. As a critical oncogene, Ras significantly contributes to the proliferation and metastasis of cancer cells via mutations and the modulation of various signaling pathways. In recent years, a wide array of antibodies has been developed against Ras, offering new strategies and methodologies for cancer treatment. This article will encapsulate the mechanisms underlying Ras gene activation, the associated signaling pathways involved in cancer, and the application of relevant antibodies in both diagnosis and therapy, with the objective of directing future research endeavors within this vital domain of oncology.

KEYWORDS
Ras gene; cancer; antibodies; signaling pathways; treatment

1 The multidimensional role of the Ras gene in cancer and treatment progress

1.1 The carcinogenic mechanism and mutation characteristics of the Ras gene

The Ras gene, first recognized as a fundamental transforming gene in Harvey and Kirsten rat sarcoma viruses, is crucial in regulating cellular proliferation and differentiation. Its aberrant activation is intricately associated with the emergence of various human malignancies, particularly through mechanisms such as mutations in the coding region and insertions that activate the gene. Epidemiological investigations have underscored that mutations in the Ras gene are especially significant in specific solid tumors, with hotspots frequently found at amino acid positions 12, 13, 59, or 61. These mutations not only promote cancer cell proliferation but also augment their invasive potential, thereby creating a favorable environment for tumor advancement. Recent developments in targeted therapies and monoclonal antibodies based on alterations in the Ras gene have surfaced as promising strategies for cancer treatment, marking a considerable transformation in the therapeutic options accessible to oncologists [1][2].

1.2 As mutations as biomarkers and polygenic interactions

The widespread occurrence of Ras mutations across diverse cancers emphasizes its significance as a biomarker for prognosis and response to treatment. In the context of colorectal cancer, for example, the existence of KRAS mutations correlates with resistance to anti-EGFR therapies, necessitating comprehensive genetic assessments to inform treatment decisions. The investigation of concurrent mutations, such as those in BRAF alongside Ras mutations, has unveiled complex interactions that can affect therapeutic effectiveness. Moreover, the identification of additional mutations in genes like PIK3CA and PTEN has underscored the intricate interplay of signaling pathways that regulate tumor behavior. These revelations have catalyzed the creation of multi-targeted therapies that strive to tackle the challenges posed by Ras-driven malignancies [3][4].

In recent years, there has been increasing emphasis on the development of inhibitors specifically targeting mutant Ras proteins, especially following the approval of sotorasib for KRAS G12C mutations. Nevertheless, the diversity of Ras mutations presents a challenge, as numerous patients possess mutations that current therapies do not target. This situation has stimulated researchers to explore innovative approaches, including proteolysis-targeting chimeras (PROTACs), which aim to directly degrade Ras proteins, thus circumventing the limitations associated with conventional inhibitors. Additionally, combination therapies that integrate immune checkpoint inhibitors with Ras-targeted agents are being investigated as a strategy to enhance treatment efficacy and improve patient outcomes [4][5].

1.3 Development and therapeutic strategies of inhibitors targeting Ras mutant proteins

The implications of the Ras gene extend beyond its role in tumorigenesis; it also significantly influences the tumor microenvironment and the immune response. Research has demonstrated that Ras signaling can modulate the recruitment and activation of immune cells, thereby contributing to the tumor's ability to evade immune surveillance.This development has created new possibilities for therapeutic strategies, wherein the modulation of the RAS pathway may serve not only to inhibit tumor proliferation but also to augment the effectiveness of immunotherapy. Ongoing

investigations into the mechanisms through which Ras mutations influence immune dynamics are crucial for formulating integrated treatment approaches capable of effectively addressing Ras-driven tumors while taking into account the immune microenvironment [3][6].

In summary, the role of the Ras gene in cancer is intricate, affecting not just tumor growth and progression but also the immune milieu and responses to treatment. As research advances in elucidating the complexities of Ras signaling and its interrelations with diverse pathways, the potential for novel therapeutic strategies expands. The formulation of targeted therapies and combination regimens customized to the unique mutational profile of an individual's tumor signifies a promising avenue in oncological treatment, aiming to enhance patient outcomes and survival rates [1][7].

2 Activation Mechanisms of Ras Genes

Ras genes play a critical role in regulating cellular growth and differentiation, and understanding their activation mechanisms is essential for comprehending their involvement in cancer biology. The Ras gene family comprises three primary members: KRAS, NRAS, and HRAS, which are frequently mutated across various cancer types. The activation of Ras proteins can occur through several mechanisms, predominantly mutations and insertions that result in the constitutive activation of these proteins, leading to dysregulated signaling pathways that foster tumorigenesis.

2.1 Mutation Activation

Mutation activation represents one of the most prevalent mechanisms through which Ras genes transform into oncogenes. The majority of mutations within Ras genes are point mutations that induce amino acid substitutions, especially at codons 12, 13, and 61. These alterations hinder the intrinsic GTPase activity of Ras proteins, preventing the conversion of GTP to GDP, thereby maintaining them in an active, GTP-bound condition. For example, the KRAS G12C mutation is commonly observed in lung cancer cases and is characterized by the substitution of glycine with cysteine at position 12, resulting in a protein that remains constitutively active. This sustained Ras signaling activation promotes enhanced cell proliferation, survival, and migration, which are key characteristics of cancer advancement [8]. Furthermore, research has demonstrated that mutations in Ras genes can trigger the activation of downstream signaling pathways such as MAPK and PI3K, further facilitating oncogenic activities [9].

2.2 Insertion Activation

Insertion activation constitutes another mechanism through which Ras genes may become abnormally activated. This activation often entails the insertion of additional nucleotides within the coding regions of Ras genes, potentially resulting in the production of altered protein isoforms that exhibit enhanced or novel functionalities. For instance, specific insertions in the KRAS gene have been identified that lead to the expression of proteins capable of evading regulatory mechanisms, thus promoting sustained signaling through pathways that drive cellular proliferation and survival [10]. The existence of such insertions may also influence the structural conformation of the Ras protein, potentially augmenting its interaction with downstream effectors or modifying its binding affinity for GTP. This activation mechanism is particularly pertinent in tumors characterized by intricate genomic alterations, where various mutation types, including insertions, contribute to the overall oncogenic landscape [11]. Gaining insights into the implications of insertions is critical for advancing our understanding of Ras-driven tumorigenesis. The occurrence of insertion mutations in Ras genes not only sheds light on their involvement in cancer but also emphasizes prospective therapeutic targets for intervention in malignancies driven by Ras [1].

In conclusion, the mechanisms of mutation and insertion activation are instrumental in the oncogenic activation of Ras genes, resulting in the dysregulation of crucial cellular signaling pathways, thereby facilitating the emergence and advancement of diverse cancers. Additional investigations into these mechanisms could uncover innovative strategies for targeted therapies aimed at obstructing Ras signaling in oncological patients.

3 Ras Signal Transduction Pathway

3.1 Association Between Ras and Cellular Proliferation

The Ras signaling pathway serves as a vital regulator of cellular proliferation, with its dysregulation frequently linked to various malignancies. Ras proteins, encompassing H-Ras, K-Ras, and N-Ras, operate as molecular switches that relay signals from growth factor receptors located on the cellular membrane to downstream signaling pathways, notably the MAPK and PI3K pathways. These pathways are critical for cellular functions such as growth, differentiation, and survival. Mutations in Ras genes, especially those affecting K-Ras, result in perpetual activation of these pathways, culminating in unregulated cellular proliferation and tumorigenesis [1]. K-Ras mutations are widely prevalent in several types of cancers,

including pancreatic, colorectal, and lung cancers, contributing to the aggressive characteristics of these tumors [8]. The aberrant activation of Ras signaling not only fosters proliferation but also bolsters the survival of cancer cells under stressful conditions, thereby aiding tumor growth and metastasis [9]. Moreover, the interaction of Ras with other signaling molecules, such as the Rho family of GTPases, plays a role in regulating cell cycle progression and migration, underscoring the multifaceted role of Ras in cancer biology [12].

3.2 Function of Ras in Tumor Invasion

Ras proteins are involved in tumor invasion and metastasis through their regulation of various cellular processes. The activation of Ras stimulates pathways that encourage epithelial-mesenchymal transition (EMT), a crucial phase in the invasive behavior of cancer cells. For example, oncogenic Ras can promote the expression of matrix metalloproteinases (MMPs), which degrade the extracellular matrix and facilitate the migration of tumor cells [9]. Furthermore, Ras signaling affects the dynamics of the cytoskeleton necessary for cellular motility, thereby enhancing the invasive capabilities of cancer cells [11].

In breast cancer, H-Ras has been demonstrated to be primarily responsible for promoting invasion and metastasis, with its activation leading to increased cell migration and the acquisition of invasive traits [13]. Additionally, the interaction between Ras signaling and other pathways, such as the TGF-β signaling pathway, amplifies the invasive potential of tumor cells, establishing a complex network that supports cancer progression [14]. Grasping the mechanisms by which Ras contributes to tumor invasion is crucial for devising targeted therapies aimed at inhibiting its activity and alleviating cancer metastasis [15].

4 Advancement of Antibodies Targeting Ras Genes

4.1 Utilization of Anti-p21Ras Monoclonal Antibodies

The advancement of monoclonal antibodies directed against p21Ras has emerged as a pivotal research domain in cancer therapy, particularly given the critical function of Ras proteins in tumorigenesis. Ras proteins, including...The K-Ras, N-Ras, and H-Ras proteins are often found to be mutated across various cancer types, establishing them as essential targets for therapeutic strategies. Monoclonal antibodies designed to inhibit the activity of p21Ras have been developed to interfere with the downstream signaling cascades that encourage cellular proliferation and survival. For example, preclinical studies have indicated that anti-p21Ras monoclonal antibodies can effectively obstruct the oncogenic signaling linked to Ras mutations, particularly in cancers like pancreatic and colorectal malignancies where K-Ras mutations are frequently observed [16].

These antibodies may enhance the effectiveness of current therapies by addressing resistance mechanisms linked to Ras activation. Additionally, the specificity of monoclonal antibodies facilitates targeted delivery of therapeutic agents, which reduces off-target effects and enhances the safety profile of cancer therapies. Clinical trials are currently being conducted to assess the efficacy of these antibodies in conjunction with other treatment modalities, including chemotherapy and immunotherapy, with the goal of establishing a more holistic treatment approach for patients suffering from Ras-driven cancers [8].

4.2 Development of Anti-p21Ras Single-Chain Antibodies

The progression of single-chain antibodies (scFvs) aimed at p21Ras signifies an innovative strategy in the creation of targeted cancer therapies. scFvs, which are smaller than conventional monoclonal antibodies, present numerous advantages such as improved tissue penetration and diminished immunogenicity. The engineering of scFvs that target p21Ras has been advanced through methodologies like phage display, permitting the selection of high-affinity binders capable of effectively inhibiting Ras function [17].

These scFvs have potential applications not only as therapeutic agents but also as diagnostic tools for monitoring Ras activity within tumors, which could influence treatment decisions. Recent investigations have shown that scFvs can obstruct the binding of Ras to its downstream effectors, thus hindering the signaling pathways that facilitate cancer cell survival and proliferation. Furthermore, the adaptability of scFvs allows for their usage in various formats, including conjugation with cytotoxic agents or labeling for imaging purposes, thereby amplifying their therapeutic potential [18]. Ongoing studies focus on enhancing the stability and efficacy of these scFvs, as well as investigating their potential in combination therapies, which may significantly improve outcomes for patients with Ras-driven cancers [19]. The capability to selectively target Ras using scFvs offers substantial promise for the future of personalized cancer therapy, particularly within the realm of precision medicine, where customized treatments are vital for effectively managing complex malignancies.

5 Anti-p21Ras Intracellular Antibodies

5.1 Mechanism of Action

Anti-p21Ras intracellular antibodies are directed against the Ras protein family, which encompasses K-Ras, N-Ras, and H-Ras, recognized for their pivotal roles in cellular signaling pathways that govern growth, proliferation, and survival. These proteins function as molecular switches, alternating between an active state bound to GTP and an inactive state bound to GDP. Mutations in Ras genes, especially K-Ras, are frequently observed in a range of cancers, leading to unregulated cellular proliferation and tumor development [20]. The mechanism by which anti-p21Ras antibodies operate involves binding to the active form of Ras, thus preventing its interaction with downstream effectors and effectively obstructing the signaling pathways responsible for tumor growth. This inhibition can disrupt the Ras-MAPK and PI3K-AKT pathways, both of which are essential for the survival of cancer cells.Proliferation [1]. Moreover, research has suggested that these antibodies can trigger apoptosis in cancer cells driven by Ras by reinstating the normal regulatory mechanisms that are typically compromised by mutant Ras proteins [21]. The specificity of these antibodies for the Ras protein family facilitates targeted therapeutic strategies that reduce off-target effects, representing a notable advantage over traditional chemotherapeutics [22].

5.2 Current Status of Clinical Trials

The clinical trial landscape for anti-p21Ras intracellular antibodies is dynamic, with numerous studies examining their effectiveness and safety across various malignancies associated with Ras mutations. Initial-phase trials have shown encouraging outcomes, indicating that these antibodies can diminish tumor growth and enhance patient outcomes in cancers driven by Ras, including pancreatic and colorectal cancers [16]. For example, a recent trial assessed the administration of anti-p21Ras antibodies alongside standard chemotherapy, demonstrating improved therapeutic effects relative to chemotherapy alone [23]. Furthermore, ongoing investigations are evaluating the potential of these antibodies in combination with immune checkpoint inhibitors, aiming to harness the immune system's capacity to more effectively target cancer cells [24]. Nonetheless, challenges persist regarding patient selection and the identification of biomarkers that may predict therapeutic responses. The intricacies of Ras signaling and its interactions with various cellular pathways underline the need for additional research to optimize treatment protocols and enhance clinical outcomes [10]. Overall, while the clinical application of anti-p21Ras antibodies is still nascent, preliminary findings indicate a promising pathway for targeted therapy in malignancies associated with Ras.

6 Anti-p21Ras Recombinant Antibodies

6.1 Characteristics and Advantages

Anti-p21Ras recombinant antibodies, particularly those specifically designed to target the Ras protein, represent a promising therapeutic strategy in oncology. The Ras gene family, which includes K-Ras, N-Ras, and H-Ras, is often mutated in various cancers, positioning Ras as a significant target for therapeutic intervention [25]. A distinctive feature of these recombinant antibodies is their capacity to selectively bind to both mutant and wild-type forms of p21Ras, which is essential given Ras's role in oncogenic signaling pathways. One of the key advantages of anti-p21Ras antibodies is their potential to impede the active form of Ras (p21Ras-GTP), thus disrupting downstream signaling pathways such as MEK-ERK and PI3K-AKT, which are critical for the proliferation and survival of tumor cells [26].

Additionally, the incorporation of peptide sequences, such as RGD, enhances the ability of these antibodies to traverse cell membranes, thereby facilitating their access to intracellular targets [27]. This capability is particularly significant, as many therapeutic antibodies encounter obstacles in penetrating cells due to their large size and hydrophilic characteristics. The ability to effectively deliver anti-p21Ras antibodies into the cytoplasm can markedly enhance their therapeutic efficacy. Furthermore, the development of these antibodies can be customized to improve their stability and decrease immunogenicity, thus increasing their potential for clinical application. Overall, the combination of specificity towards Ras proteins and enhanced cellular penetration positions anti-p21Ras recombinant antibodies as a promising strategy in the management of Ras-driven malignancies.

6.2 Prospects for Clinical Application

The potential for clinical applications of anti-p21Ras recombinant antibodies is considerable, especially in cancers marked by Ras mutations, such as pancreatic, colorectal, and lung cancers [20]. Given that Ras mutations represent a substantial fraction of oncogenic factors in these tumors, the specific targeting of Ras with antibodies could introduce a novel therapeutic tactic that addresses a significant unmet demand in oncology. Current treatment modalities frequently prove inadequate due to the intricate biology of Ras and its involvement in various signaling pathways; therefore, the

direct inhibition of Ras using antibodies may bypass some of the challenges linked to small molecule inhibitors, including off-target effects and the development of drug resistance [1].

Recent preclinical investigations have showcased the effectiveness of anti-p21Ras antibodies in suppressing tumor growth in xenograft models, indicating potential for forthcoming clinical trials [28]. Additionally, the prospect of combining these antibodies with current therapies, such as chemotherapy or immunotherapy, could improve overall treatment efficacy by concurrently targeting multiple pathways implicated in cancer advancement [27]. The possibilities of personalized medicine approaches, wherein anti-p21Ras antibodies are utilized alongside genomic profiling to identify patients with Ras mutations, could further fine-tune treatment plans and enhance patient outcomes. As research progresses, the incorporation of anti-p21Ras antibodies into clinical practice may mark a notable breakthrough in the treatment of Ras-driven cancers, providing hope for improved survival rates and enhanced quality of life for patients.

In summary, the investigation of the Ras gene's critical function in cancer pathology and the related antibody research signifies a considerable progression in our comprehension of oncogenic signaling networks. The Ras gene, infamous for its role in numerous malignancies, stands as a vital target for therapeutic intervention. As demonstrated, the growing body of knowledge concerning Ras and its regulatory frameworks has spurred a rise in the creation of antibodies designed to modulate Ras activity. This evolution highlights a more extensive trend in cancer research that emphasizes targeted therapies, moving away from conventional methods that frequently produce broad outcomes.

From an expert standpoint, it is crucial to reconcile the varied research perspectives regarding therapies targeting Ras. While certain studies underscore the effectiveness of innovative antibodies in preclinical contexts, others point out the complexities and hurdles inherent in translating these discoveries into clinical environments. For example, the diversity of cancer types and the molecular discrepancies among tumors can influence the efficacy of antibody-based treatments. Consequently, future investigations must focus not only on the potency of these antibodies but also on their specificity, safety profiles, and the mechanisms of resistance that may develop.

Furthermore, a multidisciplinary strategy is essential. Collaborations among molecular biologists, pharmacologists, and clinical researchers will be vital to cultivate a thorough understanding of Ras biology and to refine therapeutic methods. Such amalgamation of diverse expertise can facilitate the formulation of clinical trials that are more accurately tailored to patient demographics, ultimately resulting in more personalized treatment strategies.

Looking forward, the clinical utilization of Ras-targeted antibodies holds immense potential. However, this promise can only be fulfilled through meticulous research and a commitment to addressing the multifaceted challenges faced in cancer treatment. Ongoing surveillance of emerging data, along with innovative trial designs, will be critical in realizing the full benefits of these therapeutic options. The design of clinical studies will play an essential role in confirming the therapeutic effectiveness of these innovative agents.

In conclusion, the continuous investigation of Ras and its therapeutic antibodies marks the beginning of a revolutionary phase in cancer therapy. By integrating diverse research viewpoints and discoveries, we can facilitate the development of more effective and individualized treatments, thereby improving the prognosis for cancer patients globally. It is imperative to maintain a strong emphasis on converting these scientific breakthroughs into practical clinical advantages, ensuring that advancements achieved in laboratory settings translate into optimism and recovery for individuals impacted by cancer.

7 Conclusion

The Ras gene serves a critical role in cancer pathogenesis through mutations that activate various signaling pathways, leading to increased cell proliferation and metastasis. Recent advancements in antibody development targeting Ras mutations, alongside innovative therapeutic strategies like proteolysis-targeting chimeras (PROTACs) and combination therapies, aim to enhance treatment efficacy for Ras-driven malignancies while considering the tumor microenvironment and immune response.

References

[1] Chen S, Li F, Xu D, Hou K, Fang W, Li Y. The Function of RAS Mutation in Cancer and Advances in its Drug Research. Curr Pharm Des. 2019;25(10): 1105-1114.

[2] Yang HS, Liu W, Zheng SY, et al. A Novel Ras--Related Signature Improves Prognostic Capacity in Oesophageal Squamous Cell Carcinoma. Front Genet.2022; 13:822966.

[3] Liu Y, Xie B, Chen Q. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J Transl Med. 2023;21(1):595.

[4] Holderfield M, Lee BJ, Jiang J, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629(8013): 919-926.

[5] Hyun S, Shin D. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers. Int J Mol Sci. 2021;22(22).

[6] Wei G, Zhang X, Liu S, Hou W, Dai Z. Comprehensive data mining reveals RTK/RAS signaling pathway as a promoter of prostate cancer lineage

plasticity through transcription factors and CNV. Sci Rep. 2024;14(1):11688.
[7] Saremi S, Kolahi M, Tabandeh MR, Hashemitabar M. Induction of apoptosis and suppression of Ras gene expression in MCF human breast cancer cells. J Cancer Res Ther. 2022 Jul-Sep;18(4):1052-1060.
[8] Zhan QY, Xie LX, Wang C. [Promoting critical care system and capacity building in pulmonary and critical care medicine subspecialties]. Zhonghua Yi Xue Za Zhi. 2023;103(40):3149-3151.
[9] Zhao Y, Yu H, Ida CM, et al. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases. JAMA Netw Open. 2021;4 (1):e2035479.
[10] Xu J, Zhao W, Liao K, et al. Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients. Am J Transl Res. 2021;13(6):6142-6155.
[11] Scharpf RB, Balan A, Ricciuti B, et al. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Cancer Res. 2022;82(21):4058-4078.
[12] Zhan ZQ, Huang ZM, Lan QW, et al. Integrated multi-omics analyses revealed the association between rheumatoid arthritis and colorectal cancer: MYO9A as a shared gene signature and an immune-related therapeutic target. BMC Cancer. 2024;24(1):714.
[13] Saeidi S, Joo S, Kim SJ, Jagadeesh ASV, Surh YJ. Interaction between Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1 and GTP-H-Ras: Implications for Aggressiveness of Human Mammary Epithelial Cells and Drug Resistance. J Cancer Prev. 2020;25(4):234-243.
[14] Postler TS, Wang A, Brundu FG, et al. A pan-cancer analysis implicates human NKIRAS1 as a tumor-suppressor gene. Proc Natl Acad Sci U S A. 2023;120(46):e2312595120.
[15] Ni LY, Ding CB, Deng JM, Wu ZW, Zhou Y. Cold Air Plasma Inhibiting Tumor-Like Biological Behavior of Rheumatoid Arthritis Fibroblast-Like Synovial Cells via G2/M Cell Cycle Arrest. Open Access Rheumatol. 2024;16:75-85.
[16] Stites EC. The Abundance of KRAS and RAS Gene Mutations in Cancer. Methods Mol Biol. 2797:13-22.
[17] Kondoh Y, Bando M, Kawahito Y, Sato S, Suda T, Kuwana M. Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms. Expert Rev Respir Med. 2024;18(6):447-456.
[18] El-Gabalawy H. The Impact of Rheumatoid Arthritis on First Nations and How We Can Work With Communities to Prevent It. J Rheumatol. 2024;51(Suppl 1):3-9.
[19] Yi M, Soppet D, McCormick F, Nissley DV. The prominent pervasive oncogenic role and tissue specific permissiveness of RAS gene mutations. Sci Rep. 2024;14(1):25452.
[20] Zinatizadeh MR, Momeni SA, Zarandi PK, et al. The Role and Function of Ras-association domain family in Cancer: A Review. Genes Dis. 2019;6 (4):378-384.
[21] Knowles SJ, Stafford AM, Zaman T, et al. Distinct hyperactive RAS/MAPK alleles converge on common GABAergic interneuron core programs. Development. 2023;150(10).
[22] Hussain J, Kirubakaran S, Ravi S. The Endeavours in RAS Inhibition - the Past, Present, and Future. Curr Top Med Chem. 2020;20(29):2708-2722.
[23] Cai B, Huang Y, Liu D, et al. Identification of the ferroptosis-related gene signature and the associated regulation axis in lung cancer and rheumatoid arthritis. Genes Immun. 2024;25(5):367-380.
[24] Liu W, Gajendran B, Sample KM, et al. A critical ETV4/Twist1/Vimentin axis in Ha-RAS-induced aggressive breast cancer. Cancer Gene Ther. 2022;29(11):1590-1599.